Morphic Holding, which is developing oral small-molecule integrin therapeutics for various chronic diseases, announced terms for its IPO on Friday.
The Waltham, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. Insiders intend to purchase $30 million worth of shares in the offering. At the midpoint of the proposed range, Morphic Holding would command a fully diluted market value of $450 million.
Morphic Holding was founded in 2014 and it plans to list on the Nasdaq under the symbol MORF. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities are the joint bookrunners on the deal. It is expected to price during the week of June 24, 2019.
